Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...

Emraclidine is expected to reach an annual total of $192mn by 2034 in the US, as per GlobalData’s Expiry Model. Credit: ...

Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

We explore the immense potential of gamma delta T cells, and the challenges in sourcing and scaling up sufficient volumes to ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for ...

Also known as a polymyxin B haemoperfusion (PMX), Toraymyxin is a haemoperfusion device that removes endotoxin, a toxic ...

Research Grid has raised a $6.5m seed funding round led by Fuel Ventures, to improve the success rate of clinical trials.

The former health minister predicted a bright future for UK trials and outlined steps to ensure clinical research thrives.